Who are AbobotulinumtoxinA (ABO)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Onabotulinumtoxin A (BoNT), Azzalure or Dysport, Xeomin®, NAFT600 (adult), NAFT500 (adult), Botox 100 UNT Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abobotulinumtoxina-abo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AbobotulinumtoxinA (ABO) — Competitive Intelligence Brief

AbobotulinumtoxinA (ABO) (AbobotulinumtoxinA (ABO)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Dermatology, Neurology.

marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Dermatology, Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AbobotulinumtoxinA (ABO) (AbobotulinumtoxinA (ABO)) — Hexsel Dermatology Clinic. AbobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AbobotulinumtoxinA (ABO) TARGET	AbobotulinumtoxinA (ABO)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A (BoNT)	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Azzalure or Dysport	Azzalure or Dysport	Galderma R&D	marketed	Botulinum toxin type A	SNARE complex (synaptosome-associated protein)
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)
NAFT600 (adult)	NAFT600 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
NAFT500 (adult)	NAFT500 (adult)	Merz North America, Inc.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Botox 100 UNT Injection	Botox 100 UNT Injection	Brigitte Schürch	marketed	Botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

Galderma R&D · 2 drugs in this class
Hexsel Dermatology Clinic · 2 drugs in this class
Seoul National University Hospital · 2 drugs in this class
University of Utah · 2 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
EuBiologics Co.,Ltd · 1 drug in this class
Allergan · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AbobotulinumtoxinA (ABO) — Competitive Intelligence Brief. https://druglandscape.com/ci/abobotulinumtoxina-abo. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab